$44.3 Million is the total value of Knoll Capital Management, LLC's 21 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 85.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BHVN | Sell | Biohaven Pharmactl Hldg Co L | $6,251,857 | -95.4% | 450,422 | -50.0% | 14.11% | -82.3% |
| ORGS | Sell | Orgenesis, Inc. | $1,237,739 | -33.8% | 634,738 | -51.8% | 2.79% | +155.8% |
| Sell | Anavex Life Sciences Corp | $98,906 | -95.5% | 10,681 | -94.9% | 0.22% | -82.5% | |
| SNGX | Exit | Soligenix Inc. | $0 | – | -34,766 | -100.0% | -0.01% | – |
| ORMP | Exit | Oramed Pharmaceuticals Inc | $0 | – | -20,000 | -100.0% | -0.08% | – |
| ANVS | Exit | Annovis Bio Inc | $0 | – | -14,210 | -100.0% | -0.09% | – |
| Exit | Context Therapeutics Ins | $0 | – | -139,520 | -100.0% | -0.09% | – | |
| BTAI | Exit | Bioxcel Therapeutics Inc | $0 | – | -20,000 | -100.0% | -0.14% | – |
| ABEO | Exit | Abeona Therapeutics Inc | $0 | – | -88,629 | -100.0% | -0.16% | – |
| MRTX | Exit | Mirati Therapeutics, Inc | $0 | – | -5,000 | -100.0% | -0.20% | – |
| EQX | Exit | EQUINOX GOLD CORP | $0 | – | -99,000 | -100.0% | -0.21% | – |
| PAAS | Exit | PAN AMERN SILVER CORP | $0 | – | -29,500 | -100.0% | -0.27% | – |
| WPM | Exit | Wheaton Precious metals | $0 | – | -16,500 | -100.0% | -0.31% | – |
| MMX | Exit | MAVERIX METALS INC | $0 | – | -165,000 | -100.0% | -0.32% | – |
| SILV | Exit | SILVERCREST METALS INC | $0 | – | -100,000 | -100.0% | -0.32% | – |
| EIGR | Exit | Eiger Biopharmaceuticals Inc | $0 | – | -585,966 | -100.0% | -0.34% | – |
| FNV | Exit | FRANCO NEV CORP | $0 | – | -4,900 | -100.0% | -0.34% | – |
| MAG | Exit | MAG SILVER CORP | $0 | – | -48,000 | -100.0% | -0.35% | – |
| AEM | Exit | AGNICO EAGLE MINES LTD | $0 | – | -15,393 | -100.0% | -0.38% | – |
| GLW | Exit | Corning Inc | $0 | – | -26,600 | -100.0% | -0.45% | – |
| CRBP | Exit | Corbus Pharmaceuticals HLDGS | $0 | – | -5,045,870 | -100.0% | -0.49% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Aldeyra Therapeutics Inc | 35 | Q3 2023 | 31.6% |
| Corbus Pharmaceuticals HLDGS | 30 | Q3 2022 | 46.5% |
| Abeona Therapeutics Inc | 30 | Q3 2022 | 34.8% |
| Biohaven Pharmactl Hldg Co L | 26 | Q3 2023 | 79.6% |
| Entera Bio Ltd | 22 | Q3 2023 | 7.8% |
| Ampio Pharmaceuticals Inc. | 21 | Q2 2018 | 11.0% |
| Soligenix Inc. | 20 | Q3 2022 | 1.7% |
| Eiger Biopharmaceuticals Inc | 19 | Q3 2022 | 5.8% |
| Applied Therapeutics Inc | 18 | Q3 2023 | 19.7% |
| Alcobra Ltd | 18 | Q3 2017 | 6.5% |
View Knoll Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| HOOKIPA Pharma Inc. | June 20, 2023 | 5,517,385 | 6.8% |
| Applied Therapeutics Inc. | January 23, 2023 | 3,450,000 | 7.2% |
| Orgenesis Inc. | August 14, 2020 | 1,316,364 | 5.9% |
| Corbus Pharmaceuticals Holdings, Inc. | February 14, 2020 | 5,045,870 | 7.1% |
| ABEONA THERAPEUTICS INC. | February 14, 2018 | 2,359,767 | 5.0% |
| SOLIGENIX, INC. | November 13, 2017 | 870,000 | 9.9% |
| ABEONA THERAPEUTICS INC. | February 14, 2017 | 2,359,767 | 5.9% |
| ALCOBRA LTD. | February 14, 2017 | 1,205,498 | 4.4% |
| Ampio Pharmaceuticals, Inc. | February 14, 2017 | 2,738,322 | 4.8% |
| RITTER PHARMACEUTICALS INC | February 14, 2017 | 952,434 | 8.2% |
View Knoll Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-01-16 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-04 |
| 13F-HR | 2023-08-15 |
| SC 13G | 2023-06-20 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-23 |
| 13F-HR | 2022-11-14 |
View Knoll Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.